Physicians Home

Graves’ disease is characterized by the presence of TSI in the bloodstream which results in over-stimulation of the thyroid gland and low thyroid stimulating hormone (TSH) levels (hyperthyroidism)1. Eighty percent of Graves’ disease cases occur in women1, and can be difficult to diagnose because symptoms vary greatly and often mimic other illnesses2.

Thyretain is an in vitro diagnostic use test that specifically detects auto-antibodies called thyroid stimulating immunoglobulins (TSI) in patient serum. Thyretain is the first commercial test that specifically detects TSI and is intended to be used as an aid in the differential diagnosis of Graves’ disease.

1Thompson, L.D.R. (2007) Diffuse hyperplasia of the thyroid gland (Graves’ disease). ENT: Ear, Nose & Throat Journal, Vol. 86 Issue 11, p. 666-667.
2Godfrey, J. (2004) Toward Optimal Health: The Experts Discuss Thyroid Disfunction. Journal of Women’s Health, Vol. 13 Issue 2, p. 141-146.

Thyretain is manufactured and distributed by Diagnostic Hybrids. For more information about Graves' Disease, please visit the National Graves' Disease Foundation.